Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00952588 | Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients(SPARK-AML1) | completed | Phase 2 / Phase 3 | 74 | AstraZenecaINDUSTRY | 9 | Feb 24, 2020 | clinicaltrials |
| NCT00887068 | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | completed | Phase 3 | 187 | M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jan 14, 2020 |
| clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT01802333 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 754 | National Cancer Institute (NCI)NIH | 2 | Dec 19, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
| NCT01535391 | Nilotinib in PH+, BCR-, ABL+ CML Patients(CML0811) | completed | Phase 3 | 109 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | completed | Phase 3 | 144 | University of UlmOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00656448 | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | completed | Phase 3 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01460693 | Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia(SPIRIT2) | completed | Phase 3 | 814 | Newcastle UniversityOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT00952289 | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | completed | Phase 3 | 309 | Incyte CorporationINDUSTRY | 3 | Mar 12, 2018 | clinicaltrials |
| NCT02204644 | The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML | completed | Phase 3 | 400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT01382147 | Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)(AMLCG 2008) | completed | Phase 3 | 396 | Prof. Dr. Wolfgang HiddemannOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | completed | Phase 3 | 110 | Incyte CorporationINDUSTRY | 7 | Nov 14, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
| NCT01074047 | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 3 | 488 | CelgeneINDUSTRY | 18 | Aug 29, 2017 | clinicaltrials |
| NCT00516503 | Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | completed | Phase 3 | 208 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00151255 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 500 | University of UlmOTHER | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00044486 | Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) | completed | Phase 3 | 602 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 10, 2017 | clinicaltrials |
| NCT00755040 | Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder | completed | Phase 3 | 164 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01126892 | A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | completed | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2017 | clinicaltrials |
| NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(DASISION) | completed | Phase 3 | 547 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 15, 2017 | clinicaltrials |
| NCT00719563 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | completed | Phase 3 | 364 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00860639 | Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk(LAM2006IR) | completed | Phase 3 | 327 | Nantes University HospitalOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT01949805 | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera(PROUD-PV) | completed | Phase 3 | 257 | AOP Orphan Pharmaceuticals AGINDUSTRY | 14 | Nov 28, 2016 | clinicaltrials |
| NCT00121303 | Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 600 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT02736721 | Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) | completed | Phase 3 | 41 | Hoffmann-La RocheINDUSTRY | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00093990 | Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 457 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Sep 14, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 | clinicaltrials |
| NCT00003600 | Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy | completed | Phase 3 | 344 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 13, 2016 | clinicaltrials |
| NCT00006348 | Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment | completed | Phase 3 | 100 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00476541 | NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia | completed | Phase 3 | 250 | University of AarhusOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00000591 | T-Cell Depletion in Unrelated Donor Marrow Transplantation | completed | Phase 3 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Apr 15, 2016 | clinicaltrials |
| NCT01275196 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | completed | Phase 3 | 267 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT01751867 | An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome | completed | Phase 3 | 135 | Xian-Janssen Pharmaceutical Ltd.INDUSTRY | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00495287 | A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) | completed | Phase 3 | 573 | Northern Italy Leukemia GroupOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01511289 | Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | completed | Phase 3 | 242 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 4 | Feb 24, 2016 | clinicaltrials |
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients(PEN-PV) | completed | Phase 3 | 30 | AOP Orphan Pharmaceuticals AGINDUSTRY | 8 | Feb 17, 2016 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia(TEAM-ET) | completed | Phase 3 | 106 | AOP Orphan Pharmaceuticals AGINDUSTRY | 5 | Jul 29, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2020source: clinicaltrials